PGIM released its second-quarter 2025 investor letter for the PGIM Jennison Health Sciences Fund. Equities saw volatility, with the S&P 1500 Health Care Index declining 6.9% in the quarter. Health care providers & services, life sciences tools & services, biotechnology, and pharmaceuticals underperformed, while healthcare technology and medtech gained.

In the investor letter, PGIM highlighted Bristol-Myers Squibb Company (NYSE:BMY), a pharmaceutical company based in New Jersey. Bristol-Myers Squibb Company (NYSE:BMY) stock closed at $44.16 per share on September 24, 2025. The company has a market capitalization of $89.885 billion and has seen a one-month return of -5.80%.

Bristol-Myers Squibb Company (NYSE:BMY) is a global pharmaceutical company focused on multiple therapeutic areas. The company faces patent expiries for key franchises like Revlimid, Eliquis, and Opdivo. PGIM initiated a position in BMY in 2025 but exited due to concerns over trial design. BMY’s total revenues reached around $12.3 billion in Q2 2025.

Bristol-Myers Squibb Company (NYSE:BMY) is not among the 30 most popular stocks among hedge funds. However, 67 hedge fund portfolios held BMY at the end of the second quarter. While BMY shows investment potential, certain AI stocks offer greater upside potential. Investors can explore other pharma stocks recommended by billionaires or hedge fund investor letters for more insights.

Read more at Yahoo Finance: PGIM Jennison Health Sciences Fund Sold its Position in Bristol-Myers Squibb Co. (BMY) in Q2